Karbicombi

Hydrochlorothiazide and Candesartan Cilexetil, the active ingredient in Karbicombi, is an angiotensin II receptor blocker (ARB) and thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients by lowering blood pressure and reducing cardiovascular risk. GNH USA supplies Karbicombi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Karbicombi combines an ARB and a thiazide diuretic to manage high blood pressure.

Hypertension: provides effective blood pressure reduction in patients with essential hypertension. Resistant hypertension: offers additional control when monotherapy does not achieve target levels. Cardiovascular risk reduction: helps lower the risk of stroke and heart attack associated with elevated blood pressure.

Karbicombi may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild hypotension

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute renal impairment - Hyperkalemia, especially when combined with potassium‑sparing agents - Angioedema or severe allergic reactions - Persistent low blood pressure leading to syncope

Before initiating therapy with Karbicombi, several safety considerations should be observed.

Monitor blood pressure: ensure adequate control without excessive hypotension. Check electrolytes: regularly assess potassium and sodium levels. Assess renal function: evaluate creatinine and eGFR at baseline and during treatment. Avoid use in severe hepatic impairment: liver disease may alter drug metabolism. Use caution in elderly patients: increased sensitivity to blood pressure changes. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Karbicombi can interact with several other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Aliskiren (in patients with diabetes): risk of renal dysfunction and hyperkalemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - ACE inhibitors: combined use can lead to excessive potassium elevation and renal impairment.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: concurrent use can increase lithium levels, risking toxicity.